- Home
- CTRN vs CBIO Comparison
CTRN vs CBIO Comparison
Compare CTRN & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRN
- CBIO
- Stock Information
- Founded
- CTRN 1946
- CBIO 2003
- Country
- CTRN United States
- CBIO United States
- Employees
- CTRN N/A
- CBIO N/A
- Industry
- CTRN Clothing/Shoe/Accessory Stores
- CBIO
- Sector
- CTRN Consumer Discretionary
- CBIO
- Exchange
- CTRN Nasdaq
- CBIO Nasdaq
- Market Cap
- CTRN 280.0M
- CBIO 308.0M
- IPO Year
- CTRN 2005
- CBIO N/A
- Fundamental
- Price
- CTRN $32.59
- CBIO $15.06
- Analyst Decision
- CTRN Buy
- CBIO Strong Buy
- Analyst Count
- CTRN 2
- CBIO 4
- Target Price
- CTRN $24.50
- CBIO $25.50
- AVG Volume (30 Days)
- CTRN 45.3K
- CBIO 99.5K
- Earning Date
- CTRN 08-26-2025
- CBIO 07-31-2025
- Dividend Yield
- CTRN N/A
- CBIO N/A
- EPS Growth
- CTRN N/A
- CBIO N/A
- EPS
- CTRN N/A
- CBIO N/A
- Revenue
- CTRN $768,518,000.00
- CBIO N/A
- Revenue This Year
- CTRN $6.80
- CBIO N/A
- Revenue Next Year
- CTRN $4.61
- CBIO N/A
- P/E Ratio
- CTRN N/A
- CBIO N/A
- Revenue Growth
- CTRN 1.85
- CBIO N/A
- 52 Week Low
- CTRN $13.66
- CBIO $10.83
- 52 Week High
- CTRN $34.63
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- CTRN 57.81
- CBIO 63.38
- Support Level
- CTRN $31.22
- CBIO $13.50
- Resistance Level
- CTRN $32.84
- CBIO $14.26
- Average True Range (ATR)
- CTRN 1.26
- CBIO 0.74
- MACD
- CTRN 0.09
- CBIO 0.38
- Stochastic Oscillator
- CTRN 78.26
- CBIO 90.58
About CTRN Citi Trends Inc.
Citi Trends Inc is a retailer of urban fashion apparel and accessories in the United States. The company offers apparel, including fashion sportswear for men and women, as well as children, such as newborns, infants, toddlers, boys, and girls; accessories comprising handbags, jewelry, footwear, belts, intimate apparel, scrubs, and sleepwear; and functional and decorative home products, as well as beauty products, books and toys.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.